Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
deals
3
×
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
boston top stories
clinical trials
indiana blog main
indiana top stories
ipo
new york blog main
new york top stories
san diego blog main
san diego top stories
startups
wisconsin blog main
wisconsin top stories
abbvie
acetylon pharmaceuticals
akouos
alexion pharmaceuticals
allergan
alnylam pharmaceutials
alnylam pharmaceuticals
amag pharmaceuticals
ambys medicines
amunix
anirvan ghosh
arrowhead pharmaceuticals
astrazeneca
biogen
bluerock therapeutics
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
cancer
What
deal
3
×
medicines
3
×
abandoning
acquisitions
ago
aiming
ambys
announced
baggage
big
bio
biotech
ceo
collabs
companies
control
covid
cuts
daniel
deadly
debuted
development
dicerna
diseases
formed
free
future
gets
gilead
gilead’s
help
interference
introduce
ipo
launch
liver
long
make
month
new
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
deal
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?